Overview

To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

Primary Objective: To evaluate the immunogenicity of sarilumab administered as monotherapy. Secondary Objectives: - To evaluate the other safety aspects of sarilumab administered as monotherapy. - To assess the exposure of sarilumab administered as monotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Collaborator:

Regeneron Pharmaceuticals